An FDA advisory panel declined to say if GlaxoSmithKline's heart drug Advair should be approved, saying there was not enough evidence of its effectiveness in increasing survival in patients with chronic obstructive pulmonary disease. The panel did note that a study showed a "meaningful decrease" in COPD exacerbations.

Related Summaries